The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity

Kuo Hsuan Chang, Ya Jen Chiu, Shu Ling Chen, Chen Hsiang Huang, Chih Hsin Lin, Te Hsien Lin, Chi Mei Lee, Chintakunta Ramesh, Chung Hsin Wu, Chin Chang Huang, Hon Chung Fung, Yi Chun Chen, Jung Yaw Lin, Ching Fa Yao, Hei Jen Huang, Guey Jen Lee-Chen, Ming Chung Lee, Hsiu Mei Hsieh-Li

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia associated with progressive cognitive decline and memory loss. Extracellular β-amyloid (Aβ) is a major constituent of senile plaques, one of the pathological hallmarks of AD. Aβ deposition causes neuronal death via a number of possible mechanisms such as increasing oxidative stress. Therefore therapeutic approaches to identify novel Aβ aggregate reducers could be effective for AD treatment. Using a Trx-His-Aβ biochemical assay, we screened 11 synthetic indolylquinoline compounds, and found NC009-1, -2, -6 and -7 displaying potential to reduce Aβ aggregation. Treating Tet-On Aβ-GFP 293 cells with these compounds reduced Aβ aggregation and reactive oxygen species. These compounds also promoted neurite outgrowth in Tet-On Aβ-GFP SH-SY5Y cells. Furthermore, treatment with above compounds improved neuronal cell viability, neurite outgrowth, and synaptophysin expression level in mouse hippocampal primary culture under oligomeric Aβ-induced cytotoxicity. Moreover, the tested NC009-1 significantly ameliorated Aβ-induced inhibition of hippocampal long-term potentiation in mouse hippocampal slices. Our results demonstrate how synthetic indolylquinoline compounds are likely to work as chemical chaperones in Aβ-aggregation reduction and neuroprotection, providing insight into the possible applications of indolylquinoline compounds in AD treatment.

Original languageEnglish
Pages (from-to)309-319
Number of pages11
JournalNeuropharmacology
Volume101
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Alzheimer Disease
Synaptophysin
Long-Term Potentiation
Amyloid Plaques
Memory Disorders
Amyloid
Dementia
Cause of Death
Reactive Oxygen Species
Cell Survival
Oxidative Stress
Neuronal Outgrowth
Therapeutics

Keywords

  • Alzheimer's disease
  • Aβ aggregation
  • Synthetic indolylquinoline derivatives
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity. / Chang, Kuo Hsuan; Chiu, Ya Jen; Chen, Shu Ling; Huang, Chen Hsiang; Lin, Chih Hsin; Lin, Te Hsien; Lee, Chi Mei; Ramesh, Chintakunta; Wu, Chung Hsin; Huang, Chin Chang; Fung, Hon Chung; Chen, Yi Chun; Lin, Jung Yaw; Yao, Ching Fa; Huang, Hei Jen; Lee-Chen, Guey Jen; Lee, Ming Chung; Hsieh-Li, Hsiu Mei.

In: Neuropharmacology, Vol. 101, 01.02.2016, p. 309-319.

Research output: Contribution to journalArticle

Chang, KH, Chiu, YJ, Chen, SL, Huang, CH, Lin, CH, Lin, TH, Lee, CM, Ramesh, C, Wu, CH, Huang, CC, Fung, HC, Chen, YC, Lin, JY, Yao, CF, Huang, HJ, Lee-Chen, GJ, Lee, MC & Hsieh-Li, HM 2016, 'The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity', Neuropharmacology, vol. 101, pp. 309-319. https://doi.org/10.1016/j.neuropharm.2015.09.005
Chang, Kuo Hsuan ; Chiu, Ya Jen ; Chen, Shu Ling ; Huang, Chen Hsiang ; Lin, Chih Hsin ; Lin, Te Hsien ; Lee, Chi Mei ; Ramesh, Chintakunta ; Wu, Chung Hsin ; Huang, Chin Chang ; Fung, Hon Chung ; Chen, Yi Chun ; Lin, Jung Yaw ; Yao, Ching Fa ; Huang, Hei Jen ; Lee-Chen, Guey Jen ; Lee, Ming Chung ; Hsieh-Li, Hsiu Mei. / The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity. In: Neuropharmacology. 2016 ; Vol. 101. pp. 309-319.
@article{437c215254534839bbfd3c504fa214a8,
title = "The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity",
abstract = "Alzheimer's disease (AD) is the most prevalent form of dementia associated with progressive cognitive decline and memory loss. Extracellular β-amyloid (Aβ) is a major constituent of senile plaques, one of the pathological hallmarks of AD. Aβ deposition causes neuronal death via a number of possible mechanisms such as increasing oxidative stress. Therefore therapeutic approaches to identify novel Aβ aggregate reducers could be effective for AD treatment. Using a Trx-His-Aβ biochemical assay, we screened 11 synthetic indolylquinoline compounds, and found NC009-1, -2, -6 and -7 displaying potential to reduce Aβ aggregation. Treating Tet-On Aβ-GFP 293 cells with these compounds reduced Aβ aggregation and reactive oxygen species. These compounds also promoted neurite outgrowth in Tet-On Aβ-GFP SH-SY5Y cells. Furthermore, treatment with above compounds improved neuronal cell viability, neurite outgrowth, and synaptophysin expression level in mouse hippocampal primary culture under oligomeric Aβ-induced cytotoxicity. Moreover, the tested NC009-1 significantly ameliorated Aβ-induced inhibition of hippocampal long-term potentiation in mouse hippocampal slices. Our results demonstrate how synthetic indolylquinoline compounds are likely to work as chemical chaperones in Aβ-aggregation reduction and neuroprotection, providing insight into the possible applications of indolylquinoline compounds in AD treatment.",
keywords = "Alzheimer's disease, Aβ aggregation, Synthetic indolylquinoline derivatives, Therapeutics",
author = "Chang, {Kuo Hsuan} and Chiu, {Ya Jen} and Chen, {Shu Ling} and Huang, {Chen Hsiang} and Lin, {Chih Hsin} and Lin, {Te Hsien} and Lee, {Chi Mei} and Chintakunta Ramesh and Wu, {Chung Hsin} and Huang, {Chin Chang} and Fung, {Hon Chung} and Chen, {Yi Chun} and Lin, {Jung Yaw} and Yao, {Ching Fa} and Huang, {Hei Jen} and Lee-Chen, {Guey Jen} and Lee, {Ming Chung} and Hsieh-Li, {Hsiu Mei}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.neuropharm.2015.09.005",
language = "English",
volume = "101",
pages = "309--319",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity

AU - Chang, Kuo Hsuan

AU - Chiu, Ya Jen

AU - Chen, Shu Ling

AU - Huang, Chen Hsiang

AU - Lin, Chih Hsin

AU - Lin, Te Hsien

AU - Lee, Chi Mei

AU - Ramesh, Chintakunta

AU - Wu, Chung Hsin

AU - Huang, Chin Chang

AU - Fung, Hon Chung

AU - Chen, Yi Chun

AU - Lin, Jung Yaw

AU - Yao, Ching Fa

AU - Huang, Hei Jen

AU - Lee-Chen, Guey Jen

AU - Lee, Ming Chung

AU - Hsieh-Li, Hsiu Mei

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Alzheimer's disease (AD) is the most prevalent form of dementia associated with progressive cognitive decline and memory loss. Extracellular β-amyloid (Aβ) is a major constituent of senile plaques, one of the pathological hallmarks of AD. Aβ deposition causes neuronal death via a number of possible mechanisms such as increasing oxidative stress. Therefore therapeutic approaches to identify novel Aβ aggregate reducers could be effective for AD treatment. Using a Trx-His-Aβ biochemical assay, we screened 11 synthetic indolylquinoline compounds, and found NC009-1, -2, -6 and -7 displaying potential to reduce Aβ aggregation. Treating Tet-On Aβ-GFP 293 cells with these compounds reduced Aβ aggregation and reactive oxygen species. These compounds also promoted neurite outgrowth in Tet-On Aβ-GFP SH-SY5Y cells. Furthermore, treatment with above compounds improved neuronal cell viability, neurite outgrowth, and synaptophysin expression level in mouse hippocampal primary culture under oligomeric Aβ-induced cytotoxicity. Moreover, the tested NC009-1 significantly ameliorated Aβ-induced inhibition of hippocampal long-term potentiation in mouse hippocampal slices. Our results demonstrate how synthetic indolylquinoline compounds are likely to work as chemical chaperones in Aβ-aggregation reduction and neuroprotection, providing insight into the possible applications of indolylquinoline compounds in AD treatment.

AB - Alzheimer's disease (AD) is the most prevalent form of dementia associated with progressive cognitive decline and memory loss. Extracellular β-amyloid (Aβ) is a major constituent of senile plaques, one of the pathological hallmarks of AD. Aβ deposition causes neuronal death via a number of possible mechanisms such as increasing oxidative stress. Therefore therapeutic approaches to identify novel Aβ aggregate reducers could be effective for AD treatment. Using a Trx-His-Aβ biochemical assay, we screened 11 synthetic indolylquinoline compounds, and found NC009-1, -2, -6 and -7 displaying potential to reduce Aβ aggregation. Treating Tet-On Aβ-GFP 293 cells with these compounds reduced Aβ aggregation and reactive oxygen species. These compounds also promoted neurite outgrowth in Tet-On Aβ-GFP SH-SY5Y cells. Furthermore, treatment with above compounds improved neuronal cell viability, neurite outgrowth, and synaptophysin expression level in mouse hippocampal primary culture under oligomeric Aβ-induced cytotoxicity. Moreover, the tested NC009-1 significantly ameliorated Aβ-induced inhibition of hippocampal long-term potentiation in mouse hippocampal slices. Our results demonstrate how synthetic indolylquinoline compounds are likely to work as chemical chaperones in Aβ-aggregation reduction and neuroprotection, providing insight into the possible applications of indolylquinoline compounds in AD treatment.

KW - Alzheimer's disease

KW - Aβ aggregation

KW - Synthetic indolylquinoline derivatives

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84944392729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944392729&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2015.09.005

DO - 10.1016/j.neuropharm.2015.09.005

M3 - Article

C2 - 26362358

AN - SCOPUS:84944392729

VL - 101

SP - 309

EP - 319

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -